Company Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 03:37:25 2024-04-26 pm EDT			5-day change	1st Jan Change
2.436 ^USD	+0.27%		-1.75%	-60.38%

Feb. 27	Sector Update: Health Care Stocks Ease Late Afternoon	MT
Feb. 27	Top Midday Decliners	MT

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.

Number of employees: 9

Managers	Title	Age	Since
Rémy Henri Luthringer CEO	Chief Executive Officer	63	14-02-28
Geoff Race FOU	Founder	63	10-06-30
Fred Ahlholm DFI	Director of Finance/CFO	58	13-12-31
Ramana Kuchibhatla CTO	Chief Tech/Sci/R&D Officer	-	21-09-15
Michael Davidson CTO	Chief Tech/Sci/R&D Officer	74	16-11-30
Joseph Reilly COO	Chief Operating Officer	49	13-12-31

Members of the board	Title	Age	Since
Jeryl Hilleman BRD	Director/Board Member	66	18-07-16
Jan van Heek BRD	Director/Board Member	75	14-06-30
Hans-Peter Hasler BRD	Director/Board Member	68	17-12-09
David Kupfer BRD	Director/Board Member	84	15-11-01
Rémy Henri Luthringer CEO	Chief Executive Officer	63	14-02-28
Fouzia Laghrissi-Thodes BRD	Director/Board Member	61	15-05-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,993,406	5,436,892 ( 77.74 %)	0	77.74 %

Name	Equities	%	Valuation
Federated Global Investment Management Corp. 19.32 %	1,351,275	19.32 %	3 M $
Federated Global Investment Management Corp. 19.32 %	1,351,275	19.32 %	3 M $
C.H. Boehringer Sohn AG & Co. KG 18.23 %	1,275,000	18.23 %	3 M $
Fidelity Management & Research Co. LLC 7.032 %	491,746	7.032 %	1 M $
Vanguard Global Advisers LLC 2.934 %	205,154	2.934 %	529 297 $
Rémy Henri Luthringer 2.643 %	184,819	2.643 %	476 833 $
Renaissance Technologies LLC 1.533 %	107,200	1.533 %	276 576 $
BlackRock Institutional Trust Co. NA 1.039 %	72,669	1.039 %	187 486 $
UBS O'Connor LLC 0.9244 %	64,644	0.9244 %	166 782 $
Geode Capital Management LLC 0.7449 %	52,092	0.7449 %	134 397 $

Minerva Neurosciences, Inc.

1500 District Avenue

01803, Burlington

+617 600 7373

http://www.minervaneurosciences.com

address Minerva Neurosciences, Inc.(NERV)

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.43 USD

Average target price

11 USD

Spread / Average Target

+352.67%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MINERVA NEUROSCIENCES, INC.	-60.38%	16.99M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs